Camlin Fine Sciences Limited has informed the Exchange about Investor Presentation
CAMLINFINE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Camlin Fine Sciences filed its investor presentation alongside the Q3 FY26 earnings call held on February 5, 2026. Revenue grew 6.1% YoY to Rs. 4,572 million in Q3, with 9M FY26 revenue up 9% to Rs. 13,406 million. However, profitability weakened sharply — adjusted EBITDA margin fell to 6.7% from 14.4% a year ago, and the company swung to a loss of Rs. 279 million versus a Rs. 15.5 million profit in Q3 FY25, partly due to a Rs. 175 million exceptional charge. Pricing pressure in the Straights segment and US tariff challenges in Vanillin hurt margins, while Blends maintained steady growth. The company completed its 83.82% acquisition of Vinpai (natural ingredients, France) on November 30, contributing Rs. 129 million in Q3 revenue. A fire at one CFS Brazil unit on February 7 suspended operations there, and CFS Europe is likely to be liquidated to curtail discontinued-operation losses.
Near-term earnings are weak with a quarterly loss and margin compression, but the Vinpai acquisition opens a new natural-ingredients growth vertical and management expects Vanillin margins to recover as US tariffs are withdrawn. The Brazil fire incident and CFS Europe wind-down are near-term overhangs that shareholders should monitor.